Austria: Ligand Pharma acquires Apeiron Biologics for US$100m

Apeiron Biologics, an Austrian biotech company, is being acquired by US-based Ligand Pharmaceuticals for US$100m. Shareholders are also entitled to additional consideration based on future commercial and regulatory events and […]